The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor
Hynes, J., Wu, H., Pitt, S., Shen, D.R., Zhang, R., Schieven, G.L., Gillooly, K.M., Shuster, D.J., Taylor, T.L., Yang, X., McIntyre, K.W., McKinnon, M., Zhang, H., Marathe, P.H., Doweyko, A.M., Kish, K., Kiefer, S.E., Sack, J.S., Newitt, J.A., Barrish, J.C., Dodd, J., Leftheris, K.(2008) Bioorg Med Chem Lett 18: 1762-1767
- PubMed: 18313298 
- DOI: https://doi.org/10.1016/j.bmcl.2008.02.031
- Primary Citation of Related Structures:  
3BX5 - PubMed Abstract: 
A novel structural class of p38alpha MAP kinase inhibitors has been identified via iterative SAR studies of a focused deck screen hit. Optimization of the lead series generated 6e, BMS-640994, a potent and selective p38alpha inhibitor that is orally efficacious in rodent models of acute and chronic inflammation.
Organizational Affiliation: 
Bristol-Myers Squibb, Princeton, NJ 08543-4000, USA. john.hynes@bms.com